Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for trea...Show More
peer of
Metrics
marketSTOCKS
msh_idCOM:VALERIOTX
localeus
websitehttps://valeriotx.com/
ipo_date2023-06-05
primary_stock_msh_idEURONEXT:ALVIO
source_ref029f823a-d185-472b-9585-d9a4283566b8
products_or_servicesDevelopment of DNA decoy therapeutics for cancer and inflammatory diseases.